Yunding Xinyao responds to shortage of kidney disease drugs: Submitted an application to expand production capacity in February, hoping to receive approval for review as soon as possible.

Recently, a patient posted on social media that there was a shortage of Budesonide enteric capsules that they use. In response to the shortage, Yunding Xinyao stated that the company is aware of the current situation with Nifecard and is actively addressing the challenge. The company submitted a supplementary application to expand production capacity to the National Medical Products Administration in February of this year. The company is actively communicating with the medical administration in the hope of obtaining approval for review as soon as possible to ensure the continuous medication needs of the general patients. "There are already corresponding communication channels and solutions for patients, and we will communicate further information with all parties in a timely manner".